Laboratory Corporation of America Holdings (NYSE:LH) is expected to report second quarter earnings results, before market open, on Tuesday 28th July 2020.
Analysts polled by Thomson Reuters anticipate second quarter income of $ 0.99 per share.
Looking ahead, the full year income are expected at $ 11.40 per share on the revenues of $ 11979.60 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 12,012.00 million ~ $ 12,243.00 million, where as bottomline are predicted in a range of $ 11.75 ~ $ 12.15 per share
Click Here For More Historical Outlooks Of Laboratory Corporation of America Holdings
Previous Quarter Performance
Laboratory Corporation of America Holdings unwinded income for the first quarter of $ 2.37 per share, from the revenue of $ 2,824.00 million. The quarterly earnings lowered 9.54 percent while revenues boosted 1.18 percent compared with the same quarter last year.
Wall street analysts are predicting, LH to report 1Q20 income of $ 1.95 per share from revenue of $ 2744.99 million. The bottom line results beat street analysts by $ 0.42 or 21.54 percent, at the same time, top line results outshined analysts by $ 79.01 million or 2.88 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Laboratory Corporation of America Holdings
Stock Performance
According to the previous trading day, closing price of LH was $ 201.30, representing a 105.37 % increase from the 52 week low of $ 98.02 and a 0.29 % decrease over the 52 week high of $ 201.88.
The company has a market capital of $ 19.57 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”LH” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 14th July 2020, upgraded by Bank of America to Buy from Neutral rating, with $ 220.00 target price.
- On 13th July 2020, upgraded by Wolfe Research to Outperform from Peer Perform rating, with $ 217.00 target price.
- On 8th June 2020, maintained by Robert W. Baird at Outperform rating, with $ 219.00 target price.
Conference Call
Laboratory Corporation of America Holdings will be hosting a conference call at 9:00 AM eastern time on 28th July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.labcorp.com
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
